BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers. The company expects to initiate a Phase 1/2 trial by the first quarter of 2011.
"BMN 673 has been proven to be highly active in mouse xenograft models of human cancer and appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin. "We are eager to get this trial underway and to identify specific tumor types that are more susceptible to treatment with BMN 673. We have built a deep R&D pipeline and remain focused on successfully and expeditiously executing on the programs."
Study shines light on the well-being challenges faced by women in healthcare